ESRRA
ESRRA (Steroid hormone receptor ERR1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers and Adenoid cystic carcinoma.
Overview
Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter.
IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Adenoid Cystic Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ESRRA (Steroid hormone receptor ERR1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers and Adenoid cystic carcinoma.
- 1 · What it is
ESRRA (Steroid hormone receptor ERR1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers and Adenoid cystic carcinoma.
- 2 · What goes wrong in cancer
Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'.
- 3 · How drugs use it
No product in this corpus aims at ESRRA yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:3471 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P11474 (protein name, function text, keywords and locations (REST API)); IntOGen ESRRA (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerisation and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle. Location: Nucleus; Cytoplasm (UniProt). Locus 11q13.1 (HGNC).
- Salivary gland cancers: IntOGen driver in 1 cohort (ACYC)
- Adenoid cystic carcinoma: IntOGen driver in 1 cohort (ACYC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ESRRA" OR ABSTRACT:"ESRRA" OR TITLE:"estrogen related receptor alpha" OR ABSTRACT:"estrogen related receptor alpha" OR TITLE:"Steroid hormone receptor ERR1" OR ABSTRACT:"Steroid hormone receptor ERR1" OR TITLE:"ERR1" OR ABSTRACT:"ERR1" OR TITLE:"ERRalpha" OR ABSTRACT:"ERRalpha" OR TITLE:"NR3B1" OR ABSTRACT:"NR3B1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ESRRA, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialClinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
- TargetTYW2
Shares Salivary gland cancers, IntOGen.
- TrialStudy of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
- TargetSMARCA2
Shares Salivary gland cancers, IntOGen.
- TargetCRTC1
Shares Adenoid cystic carcinoma, Salivary gland cancers, IntOGen.
- TreatmentREM-422
- TargetTRRAP
Shares Salivary gland cancers, IntOGen.
- TargetNOTCH2
Shares Salivary gland cancers, IntOGen.